Many milestones in medical history rest on animal modeling of human diseases. The SARS-CoV-2 pandemic has evoked a tremendous investigative effort primarily centered on clinical studies. However, several animal SARS-CoV-2/COVID-19 models have been developed and pre-clinical findings aimed at supporting clinical evidence rapidly emerge. In this review, we characterize the existing animal models exposing their relevance and limitations as well as outline their utility in COVID-19 drug and vaccine development. Concurrently, we summarize the status of clinical trial research and discuss the novel tactics utilized in the largest multi-center trials aiming to accelerate generation of reliable results that may subsequently shape COVID-19 clinical treatment practices. We also highlight areas of improvement for animal studies in order to elevate their translational utility. In pandemics, to optimize the use of strained resources in a short time-frame, optimizing and strengthening the synergy between the preclinical and clinical domains is pivotal.
Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge / Winkler, M. S.; Skirecki, T.; Brunkhorst, F. M.; Cajander, S.; Cavaillon, J. -M.; Ferrer, R.; Flohe, S. B.; Garcia-Salido, A.; Giamarellos-Bourboulis, E. J.; Girardis, M.; Kox, M.; Lachmann, G.; Martin-Loeches, I.; Netea, M. G.; Spinetti, T.; Schefold, J. C.; Torres, A.; Uhle, F.; Venet, F.; Weis, S.; Scherag, A.; Rubio, I.; Osuchowski, M. F.. - In: EBIOMEDICINE. - ISSN 2352-3964. - 66:(2021), pp. N/A-N/A. [10.1016/j.ebiom.2021.103291]
Bridging animal and clinical research during SARS-CoV-2 pandemic: A new-old challenge
Girardis M.;
2021
Abstract
Many milestones in medical history rest on animal modeling of human diseases. The SARS-CoV-2 pandemic has evoked a tremendous investigative effort primarily centered on clinical studies. However, several animal SARS-CoV-2/COVID-19 models have been developed and pre-clinical findings aimed at supporting clinical evidence rapidly emerge. In this review, we characterize the existing animal models exposing their relevance and limitations as well as outline their utility in COVID-19 drug and vaccine development. Concurrently, we summarize the status of clinical trial research and discuss the novel tactics utilized in the largest multi-center trials aiming to accelerate generation of reliable results that may subsequently shape COVID-19 clinical treatment practices. We also highlight areas of improvement for animal studies in order to elevate their translational utility. In pandemics, to optimize the use of strained resources in a short time-frame, optimizing and strengthening the synergy between the preclinical and clinical domains is pivotal.File | Dimensione | Formato | |
---|---|---|---|
PIIS2352396421000840.pdf
Open access
Tipologia:
VOR - Versione pubblicata dall'editore
Dimensione
839.61 kB
Formato
Adobe PDF
|
839.61 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris